HK1248115A1 - 一种使用免疫调节治疗癌症的新颖方法 - Google Patents

一种使用免疫调节治疗癌症的新颖方法 Download PDF

Info

Publication number
HK1248115A1
HK1248115A1 HK18107658.8A HK18107658A HK1248115A1 HK 1248115 A1 HK1248115 A1 HK 1248115A1 HK 18107658 A HK18107658 A HK 18107658A HK 1248115 A1 HK1248115 A1 HK 1248115A1
Authority
HK
Hong Kong
Prior art keywords
immunomodulation
cancer
treatment
novel approach
combination
Prior art date
Application number
HK18107658.8A
Other languages
English (en)
Chinese (zh)
Inventor
Vimal D. Mehta
Luca Rastelli
Aparna Katoch SAPRA
Original Assignee
Bioxcel Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics, Inc. filed Critical Bioxcel Therapeutics, Inc.
Publication of HK1248115A1 publication Critical patent/HK1248115A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
HK18107658.8A 2015-07-16 2016-07-18 一种使用免疫调节治疗癌症的新颖方法 HK1248115A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562193348P 2015-07-16 2015-07-16
US201562193348P 2015-07-16
US201562204495P 2015-08-13 2015-08-13
US201562204495P 2015-08-13
PCT/US2016/042798 WO2017011831A1 (en) 2015-07-16 2016-07-18 A novel approach for treatment of cancer using immunomodulation

Publications (1)

Publication Number Publication Date
HK1248115A1 true HK1248115A1 (zh) 2018-10-12

Family

ID=57757732

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107658.8A HK1248115A1 (zh) 2015-07-16 2016-07-18 一种使用免疫调节治疗癌症的新颖方法

Country Status (15)

Country Link
US (3) US11564986B2 (enExample)
EP (1) EP3322448A4 (enExample)
JP (1) JP7032311B2 (enExample)
KR (1) KR20180036974A (enExample)
CN (3) CN116059219A (enExample)
AU (3) AU2016293674B2 (enExample)
BR (1) BR112018000917A2 (enExample)
CA (1) CA2991628C (enExample)
HK (1) HK1248115A1 (enExample)
MA (1) MA42459A (enExample)
MX (2) MX2018000619A (enExample)
NZ (1) NZ739503A (enExample)
RU (1) RU2711380C2 (enExample)
WO (1) WO2017011831A1 (enExample)
ZA (2) ZA201800688B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015296214B2 (en) * 2014-08-01 2019-11-07 Board Of Regents, The University Of Texas System Methods and therapeutic combinations for treating tumors
NZ739503A (en) 2015-07-16 2023-06-30 Bioxcel Therapeutics Inc A novel approach for treatment of cancer using immunomodulation
EP3393475B1 (en) 2015-12-24 2025-02-05 Corvus Pharmaceuticals, Inc. Ciforadent alone or in combination with atezolizumab for use in treating cancer
WO2018049014A1 (en) * 2016-09-07 2018-03-15 Trustees Of Tufts College Dash inhibitors, and uses related thereto
MX2019003755A (es) * 2016-10-06 2019-08-12 Pfizer Regimen de dosificacion de avelumab para el tratamiento de cancer.
ES2988845T3 (es) * 2017-01-09 2024-11-21 Onkosxcel Therapeutics Llc Procedimientos predictivos y diagnósticos para cáncer de próstata
NZ757538A (en) * 2017-03-28 2023-07-28 Dicerna Pharmaceuticals Inc Reducing beta-catenin expression to potentiate immunotherapy
WO2018187484A1 (en) 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
US11559537B2 (en) 2017-04-07 2023-01-24 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
BR112020009363A2 (pt) * 2017-11-13 2020-10-27 Bioxcel Therapeutics, Inc. métodos e composições para tratar câncer por modificação de múltiplos braços do sistema imunológico
MX2020006128A (es) * 2017-12-15 2020-09-21 Praxis Biotech LLC Inhibidores de la proteina de activacion de fibroblastos.
WO2019202473A1 (en) * 2018-04-16 2019-10-24 Université de Lausanne Ucp2 inducing agents for the treatment of cancer resistant to immune checkpoint blockade
JP2022500480A (ja) * 2018-09-28 2022-01-04 カニムグイド セラピューティクス エービー ペプチド阻害剤の医薬製剤
GB201819853D0 (en) * 2018-12-05 2019-01-23 Innovation Ulster Ltd Therapy
BR112021011205A2 (pt) * 2018-12-10 2021-08-24 Bioxcel Therapeutics, Inc. Nova abordagem para tratamento de câncer usando imunomodulação
WO2020123477A1 (en) * 2018-12-10 2020-06-18 Bioxcel Therapeutics, Inc. Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
EP3898654A4 (en) 2018-12-21 2022-10-26 Praxis Biotech LLC FIBROBLAST ACTIVATION PROTEIN INHIBITORS
US12396992B2 (en) 2019-01-07 2025-08-26 Intra-Cellular Therapies, Inc. Organic compounds
US20230338402A1 (en) * 2020-02-07 2023-10-26 Bioxcel Therapeutics, Inc. Treatment regimen for cancer using immunomodulation
IL295489A (en) * 2020-02-14 2022-10-01 Bioxcel Therapeutics Inc Systems and methods for detection and prevention of emergence of agitation
EP4117667B1 (en) * 2020-03-13 2024-12-18 The Board Of Regents Of The University Of Texas System Sequential treatment of cancers using 6-thio-dg and checkpoint inhibitors
CN115943312A (zh) * 2020-05-07 2023-04-07 法国居里学院 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途
US20220257759A1 (en) * 2021-02-17 2022-08-18 Bioxcel Therapeutics, Inc. Treatment of sarcoma using immunomodulation
TW202345857A (zh) * 2022-03-08 2023-12-01 美商昂科斯克塞爾醫療有限責任公司 他波司他之穩定調配物
JP2025509446A (ja) * 2022-03-11 2025-04-11 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2024107832A2 (en) * 2022-11-16 2024-05-23 Onkosxcel Therapeutics, Llc Treatment regimen for treating cancers
WO2024155790A2 (en) * 2023-01-18 2024-07-25 Onkosxcel Therapeutics, Llc Novel approach for treatment of cancer using immunomodulation
WO2025076445A1 (en) * 2023-10-04 2025-04-10 Agenus Inc. Anti-fap antibodies and methods of use thereof
CN117482249B (zh) * 2023-11-28 2024-09-17 辽宁中医药大学 一种肝癌干细胞niche响应型逐级靶向脂质体及其应用
CN117695397A (zh) * 2024-02-06 2024-03-15 北京肿瘤医院(北京大学肿瘤医院) 用于提高肿瘤靶向cldn18.2治疗疗效的药物

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
FR2703251B3 (fr) 1993-03-31 1995-08-04 Vacsyn Sa Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine .
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
SI2112166T1 (sl) 1998-12-23 2019-05-31 Pfizer Inc. Človeška monoklonska protitelesa proti CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
EP1445264B1 (en) 2001-07-31 2011-09-14 Ono Pharmaceutical Co., Ltd. Substance specific to pd-1
BR0309254A (pt) 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
EP1793858A4 (en) 2004-09-08 2008-12-10 Univ Ohio State Res Found HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007014754A1 (en) 2005-08-02 2007-02-08 I.D.M. Immuno-Designed Molecules Process for the preparation of liposomal formulations
WO2007058957A2 (en) 2005-11-10 2007-05-24 Point Therapeutics, Inc Boroproline compound and cytokine combination therapy
WO2007059099A2 (en) 2005-11-14 2007-05-24 Point Therapeutics, Inc. Boroproline combination therapy for cancer
JP2009522372A (ja) 2006-01-09 2009-06-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ワクチンおよび腫瘍免疫療法のためのｔｎｆｒｓｆ、ｔｌｒ、ｎｌｒ、ｒｈｒ、プリン受容体、およびサイトカイン受容体アゴニストの組み合わせ免疫刺激剤
WO2007127204A2 (en) * 2006-04-24 2007-11-08 Dara Biosciences, Inc. Methods and compositions relating to immunostimulation
WO2008033368A2 (en) 2006-09-12 2008-03-20 Dara Biosciences, Inc. Boroproline compound and cytokine combination therapy
WO2008066729A2 (en) * 2006-11-22 2008-06-05 Dara Biosciences, Inc. Boronic acid containing compositions
WO2008070564A1 (en) 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
CA2718573C (en) 2007-04-12 2020-07-14 The Brigham And Women's Hospital, Inc. Targeting abcb5 for cancer therapy
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
AU2009204194A1 (en) 2008-01-08 2009-07-16 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
CA2736816C (en) 2008-09-12 2018-05-22 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
HUE030807T2 (en) 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
WO2010065711A1 (en) 2008-12-04 2010-06-10 Adimab, Inc. An abcb5 epitope and antibodies thereto for the treatment of cancer
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
JP6066732B2 (ja) 2010-03-05 2017-01-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
TW201134481A (en) 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN107090029B (zh) 2010-11-11 2021-07-13 港大科桥有限公司 可溶性 pd-1变体、融合构建体及其用途
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
RU2013149800A (ru) * 2011-04-08 2015-05-20 Афраксис Холдингз, Инк. 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения расстройств нервной системы и рака
BR122022000334B1 (pt) 2011-08-01 2023-03-21 Genentech, Inc Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek
CA2856379A1 (en) * 2011-11-22 2013-05-30 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
KR102702287B1 (ko) 2012-05-15 2024-09-04 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
CA2907181C (en) * 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
PT2992017T (pt) 2013-05-02 2021-01-29 Anaptysbio Inc Anticorpos dirigidos contra a morte programada 1 (pd-1)
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
RS63571B9 (sr) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
CN104558177B (zh) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
IL292510A (en) * 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
JP2016536361A (ja) * 2013-11-06 2016-11-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
EP3082853A2 (en) * 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
RU2732604C2 (ru) 2013-12-20 2020-09-21 Интервет Интернэшнл Б.В. Антитела к pd-1 собак
SMT201800643T1 (it) * 2013-12-24 2019-01-11 Bristol Myers Squibb Co Composti triciclici come agenti anticancro
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MX375123B (es) 2014-02-14 2025-03-06 Immune Design Corp Composición para usarse en mejorar la respuesta inmune contra el cáncer.
HRP20210377T1 (hr) 2014-02-21 2021-04-16 Nektar Therapeutics Il-2rbeta-selektivni agonisti u kombinaciji s anti-ctla-4 protutijelom ili anti-pd-1 protutijelom
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
WO2016019270A1 (en) 2014-07-31 2016-02-04 Academia Sinica An antagonistic pd-1 aptamer and its applications in cancer therapy related applications
ES2819451T3 (es) 2014-08-08 2021-04-16 Univ Leland Stanford Junior Agentes PD-1 de alta afinidad y procedimientos de uso
US20170239351A1 (en) * 2014-08-11 2017-08-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
WO2016077397A2 (en) 2014-11-11 2016-05-19 Sutro Biopharma, Inc. Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
US20160148513A1 (en) 2014-11-20 2016-05-26 Here Global B.V. Method and apparatus for providing line-of-sight obstruction notification for navigation
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3237446B1 (en) 2014-12-22 2021-05-05 PD-1 Acquisition Group, LLC Anti-pd-1 antibodies
CN104479020B (zh) 2014-12-26 2019-08-02 上海复宏汉霖生物技术股份有限公司 一种抗pd-1人源抗体
WO2016130986A1 (en) 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
CN104761633B (zh) 2015-03-25 2018-11-27 新乡学院 阻断猪pd-1/pd-l1通路的多肽及其应用
US20180134771A1 (en) 2015-05-07 2018-05-17 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer
KR20180025888A (ko) 2015-06-08 2018-03-09 제넨테크, 인크. 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
CN105061597B (zh) 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
AU2016280003B2 (en) 2015-06-16 2021-09-16 Merck Patent Gmbh PD-L1 antagonist combination treatments
NZ739503A (en) 2015-07-16 2023-06-30 Bioxcel Therapeutics Inc A novel approach for treatment of cancer using immunomodulation
WO2017020974A1 (en) 2015-08-03 2017-02-09 Institut Pasteur Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
WO2017040670A1 (en) 2015-09-01 2017-03-09 Ifm Therapeutics, Inc Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same
US10954300B2 (en) 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
IL295423B2 (en) 2015-10-01 2023-11-01 Heat Biologics Inc Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins
CN105175544B (zh) 2015-10-20 2021-04-09 安徽瀚海博兴生物技术有限公司 一种抗pd-1人源化单克隆抗体及其应用
WO2017079303A1 (en) 2015-11-02 2017-05-11 The Cleveland Clinic Foundation Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer
CA3010987A1 (en) 2016-01-08 2017-07-13 Replimune Limited Oncolytic herpes simplex virus type 1 strain
US20190008918A1 (en) 2016-03-08 2019-01-10 Bioxcel Corporation Immunomodulation therapies for cancer
WO2018049014A1 (en) 2016-09-07 2018-03-15 Trustees Of Tufts College Dash inhibitors, and uses related thereto
ES2837755T3 (es) 2016-09-14 2021-07-01 Abbvie Biotherapeutics Inc Anticuerpos anti-PD-1
ES2988845T3 (es) 2017-01-09 2024-11-21 Onkosxcel Therapeutics Llc Procedimientos predictivos y diagnósticos para cáncer de próstata
BR112020009363A2 (pt) 2017-11-13 2020-10-27 Bioxcel Therapeutics, Inc. métodos e composições para tratar câncer por modificação de múltiplos braços do sistema imunológico
WO2020123477A1 (en) 2018-12-10 2020-06-18 Bioxcel Therapeutics, Inc. Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
BR112021011205A2 (pt) 2018-12-10 2021-08-24 Bioxcel Therapeutics, Inc. Nova abordagem para tratamento de câncer usando imunomodulação

Also Published As

Publication number Publication date
MX2018000619A (es) 2019-03-06
AU2020200953A1 (en) 2020-02-27
BR112018000917A2 (pt) 2018-09-11
RU2018105985A (ru) 2019-08-16
US20250213681A1 (en) 2025-07-03
EP3322448A1 (en) 2018-05-23
AU2016293674B2 (en) 2019-11-21
RU2711380C2 (ru) 2020-01-16
ZA201800688B (en) 2020-08-26
KR20180036974A (ko) 2018-04-10
US20170266280A1 (en) 2017-09-21
US20240000928A1 (en) 2024-01-04
NZ739503A (en) 2023-06-30
WO2017011831A1 (en) 2017-01-19
CA2991628A1 (en) 2017-01-19
AU2016293674A1 (en) 2018-02-22
EP3322448A4 (en) 2019-03-06
CN108136025A (zh) 2018-06-08
ZA201903442B (en) 2021-04-28
AU2020200953B2 (en) 2021-12-23
US11564986B2 (en) 2023-01-31
MA42459A (fr) 2018-05-23
MX2022010270A (es) 2022-09-19
CA2991628C (en) 2020-04-07
RU2019144144A (ru) 2020-03-19
CN108136025B (zh) 2022-09-06
CN116059218A (zh) 2023-05-05
JP2018521135A (ja) 2018-08-02
CN116059219A (zh) 2023-05-05
RU2018105985A3 (enExample) 2019-08-16
JP7032311B2 (ja) 2022-03-08
AU2022201950A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
MX2022010270A (es) Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
ZA201906269B (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MY194586A (en) Anti-garp antibody
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
TW201613887A (en) Antiproliferative compounds and methods of use thereof
HK1258570A1 (zh) 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
WO2017139570A8 (en) Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine
WO2018083220A3 (en) Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2018015172A (es) Metodos para tratar cancer pancreatico.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
HK1252514A1 (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
MX2019003751A (es) Proteina terapeutica.